Deals Of The Week: Astellas/OSI, Pfizer/Tekmira, Teva/ratiopharm...
Executive Summary
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com
You may also be interested in...
Lilly/Acrux's Axiron Delivers Testosterone Differently, But The Label Remains The Same
Newly-approved testosterone therapy product is delivered via the armpit, but FDA says the same precautions are necessary as for other products applied to the shoulders and upper arms.
Lilly/Acrux's Axiron Delivers Testosterone Differently, But The Label Remains The Same
Newly-approved testosterone therapy product is delivered via the armpit, but FDA says the same precautions are necessary as for other products applied to the shoulders and upper arms.
Pharma and Academia: Finding New Ways to Join Hands for Mutual Benefit
As Big Pharmas seek to hedge their development risk and look for more externally sourced programs, partnerships with academic institutions are one of the many ingredients in the R&D secret sauce. Such deals aren't the academic-industry tie-ups of yore-where Big Pharma sought small money partnerships without giving a lot back to their academic partners. Business development execs view them as yet another way to access critically important innovation.